Highest-materiality recent filing
Design Therapeutics reports Q2 net loss of $20.2M; modifies RESTORE-FA trial, delays FECD data
Net loss of $20.2M for Q2 2026; cash and securities of $207.4M at quarter-end.
Design Therapeutics reports positive Phase 1/2 data for DT-216P2 in Friedreich ataxia
After 4 weeks at 1 mpk, mFARS improved 6.4 points, Upright Stability Score 2.7 points, fatigue >5 points (PROMIS).
Design Therapeutics reports Q4 2025 net loss of $16.0M; cash $219.8M funds operations into 2029
Full-year 2025 net loss $69.8M; R&D expenses $59.1M, G&A $20.3M.
Design Therapeutics plans DT-818 DM1 trial H1 2026; Q3 net loss $17M; cash $206M
DT-818 nominated as DM1 development candidate; >90% reduction in toxic RNA foci in preclinical studies.
Design Therapeutics Q2 net loss $19.1M; FDA clinical hold on DT-216P2 US IND; cash $216.3M
Net loss of $19.1M for Q2 2025; R&D expense $15.7M, G&A $5.8M; cash and securities $216.3M as of June 30, 2025.
Design Therapeutics Q1 net loss $17.7M; cash $229.7M funds into 2029
R&D expenses $15.4M, G&A $5.0M for Q1 2025; net loss $17.7M.
Design Therapeutics Q4 2024 net loss $13.7M; cash $245.5M; FA and FECD trials advancing
Net loss of $13.7M for Q4 2024 and $49.6M for full year 2024; R&D expense $44.4M, G&A $18.0M.
Design Therapeutics Q2 net loss $11.8M; cash $261M; FA and FECD programs on track
Net loss $11.8M for Q2 2024; R&D expense $10.5M, G&A expense $4.5M.
Net loss $11.8M in Q4 2023 and $66.9M for full year; cash & securities $281.8M funding 5-year runway.
Net loss of $15.8M for Q3 2023; R&D expenses $13.3M, G&A expenses $5.6M.
Design Therapeutics Reports Q2 2023 Results, Pipeline Progress with DT-216 and DT-168
Initial Phase 1 data for DT-216 in Friedreich Ataxia showed significant dose-related FXN mRNA increase in skeletal muscle (p<0.05)
Design Therapeutics Q4 net loss $17.3M; FY2022 net loss $63.3M; cash $330M; DT-216 MAD data mid-2023
R&D expenses $14.3M (Q4) and $48.6M (FY2022); G&A $5.1M (Q4) and $19.0M (FY2022).
Design Therapeutics reports Q3 net loss $17.7M; cash $344.2M; DT-216 Phase 1 SAD data in Dec 2022
Net loss of $17.7M for Q3 2022; R&D expenses $14.3M, G&A expenses $4.9M.
Design Therapeutics Q1 net loss $13.3M; cash $371.2M; DT-216 Phase 1 underway
Net loss of $13.3M for Q1 2022; R&D expenses $8.8M, G&A $4.6M.
Design Therapeutics reports FY2021 net loss $35.5M, IND cleared for DT-216 Phase 1 trial
Net loss $35.5M for FY2021 ($11.1M in Q4); cash and investments $384.1M at Dec 31, 2021.
Design Therapeutics Q2 net loss $7.6M; FA GeneTAC on track for H1 2022 clinical start
Net loss $7.6M; R&D expenses $5.0M, G&A $2.7M; cash & investments $402.8M.
agreed to the resignation of Dr. Siffert from all offices of the Company and from the Board, effective immediately
On August 25, 2023, the Board appointed Pratik Shah, Ph.D., as the Company’s President, Chief Executive Officer and principal financial officer.
the Board appointed Simeon George, M.D., as the Company’s lead independent director
Upon the Effective Date, which is expected to be September 13, 2021, Dawn Giangiulio, the Company’s Controller and interim principal accounting officer, will discontinue serving as the Company’s interim principal accounting officer.
On August 18, 2021, the Board of Directors (the “Board”) of Design Therapeutics, Inc. (the “Company”) appointed Julie Burgess as the Company’s Chief Accounting Officer and principal accounting officer, effective upon the date she commences employment with the Company (the “Effective Date”).
On August 2, 2021, Justin Thacker notified Design Therapeutics, Inc. (the “Company”) of his intention to resign as the Company’s VP, Finance and from his position as the Company’s principal accounting officer, effective August 13, 2021, to pursue another opportunity.
Effective as of August 13, 2021, Dawn Giangiulio, the Company’s Controller, will become the Company’s interim principal accounting officer for purposes of the Securities Exchange Act of 1934, as amended.
Max materiality 0.80 · Median 0.55 · Most common event earnings